CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Cash flows from operating activities:
Net (loss) income	$ (291,766)	$ (4,650)	$ 38,671
Adjustments to reconcile net (loss) income to net cash provided by operating activities, including discontinued operations:
Loss on extinguishment of debt	0	14,126	0
Depreciation and amortization	32,331	48,023	45,465
Amortization of favorable and unfavorable lease intangibles	(2,023)	(1,945)	(1,824)
Provision for losses on accounts receivable	25,796	21,175	21,196
Loss on sale of assets, including discontinued operations, net	1,926	847	605
Loss on asset impairment	317,091	0	0
Stock-based compensation expense	8,360	6,300	5,810
Deferred taxes	8,154	(1,590)	27,003
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(15,561)	(18,945)	(33,547)
Restricted cash	(1,201)	3,176	10,628
Prepaid expenses and other assets	(178)	5,671	2,940
Accounts payable	5,567	(1,842)	(8,390)
Accrued compensation and benefits	(552)	2,519	(2,989)
Accrued self-insurance obligations	3,377	17,890	7,759
Other accrued liabilities	(5,760)	(9,919)	(3,196)
Other long-term liabilities	(2,517)	(928)	(1,223)
Net cash provided by operating activities	83,044	79,908	108,908
Cash flows from investing activities:
Capital expenditures	(44,146)	(53,528)	(54,312)
Purchase of leased real estate	0	0	3,275
Proceeds from sale of assets held for sale	1,809	0	2,174
Acquisitions, net of cash acquired	(1,356)	(13,894)	(14,936)
Net cash used for investing activities	(43,693)	(67,422)	(70,349)
Cash flows from financing activities:
Borrowings of long-term debt	0	435,500	20,822
Principal repayments of long-term debt and capital lease obligations	(61,201)	(590,939)	(46,292)
Payment to non-controlling interest	0	(2,025)	(311)
Distribution to non-controlling interest	0	(105)	(549)
Distribution to Sabra Health Care REIT, Inc.	0	(66,862)	0
Dividend to stockholders	0	(9,996)	0
Proceeds from issuance of common stock	0	225,393	101
Deferred financing costs	(1,405)	(26,772)	0
Net cash used for by financing activities	(62,606)	(35,806)	(26,229)
Net (decrease) increase in cash and cash equivalents	(23,255)	(23,320)	12,330
Cash and cash equivalents at beginning of period	81,163	104,483	92,153
Cash and cash equivalents at end of period	57,908	81,163	104,483
Supplemental disclosure of cash flow information:
Interest payments	18,529	47,160	48,781
Capitalized interest	454	614	523
Income taxes paid, net	$ 1,462	$ 103	$ 3,484